Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Sensus Healthcare Inc Market Cap
From what 2 stock analysts predict, the share price for Sensus Healthcare Inc (SRTS) might increase by 75.21% in the next year. This is based on a 12-month average estimation for SRTS. Price targets go from $10 to $12. The majority of stock analysts believe SRTS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assigned SRTS 2 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Sensus Healthcare Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SRTS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of SRTS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Yi Chen HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 12, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $10 | Maintains | May 13, 2024 |
| Anthony Vendetti Maxim Group | Buy | $10 | Maintains | May 10, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $8 | Reiterates | Nov 13, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $8 | Maintains | Aug 7, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $10 | Reiterates | May 4, 2023 |
| Ben Haynor Alliance Global Partners | Buy | $7 | Maintains | May 4, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $16 | Reiterates | Feb 10, 2023 |
| Ben Haynor Alliance Global Partners | Buy | $14.5 | Maintains | Feb 10, 2023 |
| Ben Haynor Alliance Global Partners | Buy | $16.5 | Maintains | Nov 4, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $16 | Maintains | May 6, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $13 | Maintains | Mar 3, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Maintains | Feb 14, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $10 | Maintains | Dec 2, 2021 |
| Yi Chen HC Wainwright & Co. | Buy | $9 | Maintains | Nov 5, 2021 |
| Yi Chen HC Wainwright & Co. | Buy | $7 | Maintains | Aug 6, 2021 |
| Yi Chen HC Wainwright & Co. | Buy | $6 | Maintains | Mar 1, 2021 |
| Scott Henry Roth Capital | Buy | $6 | Maintains | Feb 26, 2021 |
HC Wainwright & Co. | Buy | $4 | Maintains | Nov 9, 2020 |
B. Riley FBR | Neutral | Maintains | May 11, 2020 |
When did it IPO
2016
Staff Count
35
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Joseph C. Sardano
Market Cap
$104.6M
In 2023, SRTS generated $24.4M in revenue, which was a decrease of -45.20% from the previous year. This can be seen as a signal that SRTS's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
